Abstract: OBJECTIVE To analyze the epidemiology and drug resistance of ventilator-associated pneumonia caused by carbapenem-resistant Klebsiella pneumoniae (CRKP) isolated from intensive care unit (ICU), so as to provide evidence for clinical treatment. METHODS A total of 80 patients with K. pneumoniae infection were selected in ICU from Mar. 2014 to Sep. 2016, and patients with K.pneumoniae infection susceptible to carbapenem antibiotics (CSKP) were also selected as control group. The clinical data were retrospectively analyzed, and the susceptibility of K. pneumoniae to commonly used antimicrobials was analyzed. RESULTS By comparing the clinical data of VAP patients with CRKP and CSKP, it was found that there were significant differences between the two groups in the time of admission to ICU, the time of mechanical ventilation, the type and time of using antimicrobials (P<0.05). By the susceptibility testing of CRKP, CRKP had higher resistance to imipenem, ceftazidime, ceftriaxone, aztreonam, piperacillin, levofloxacin, cefoperazone/sulbactam, ciprofloxacin and sulfamethoxazole/trimethoprim, and had higher sensitivity to tigecycline, amikacin, and gentamicin. CONCLUSION The CRKP-induced ventilator-induced infection in ICU is affected by many factors, and has higher resistance to imipenem, ceftazidime, ceftriaxone and other drugs. In order to effectively control the occurrence of infection, clinically rational drug use should be based on the results of drug susceptibility testing.